Cerebral metabolic differences associated with cognitive impairment in Parkinson's disease

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Tang, Yilin ^a   Ge, Jingjie ^a   Liu, Fengtao ^a   Wu, Ping ^a   Guo, Sisi ^a   Liu, Zhenyang ^a   Wang, Yixuan ^a   Wang, Ying ^a   Ding, Zhengtong ^a   Wu, Jianjun ^a   Zuo, Chuantao ^a   Wang, Jian ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; LEVODOPA;

ADULT; ANGULAR GYRUS; ARTICLE; ASSESSMENT OF HUMANS; BRAIN METABOLISM; CHINESE; CLINICAL ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; FRONTAL GYRUS; FRONTAL LOBE; GERIATRIC DEPRESSION RATING SCALE; GLUCOSE METABOLISM; HOEHN AND YAHR SCALE; HUMAN; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MOTOR DYSFUNCTION; OCCIPITAL LOBE; PARAHIPPOCAMPAL GYRUS; PARIETAL LOBE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; POSTCENTRAL GYRUS; POSTERIOR CINGULATE; PRECUNEUS; PRIMARY MOTOR CORTEX; SUPERIOR FRONTAL GYRUS; SUPERIOR TEMPORAL GYRUS; SUPRAMARGINAL GYRUS; TEMPORAL GYRUS; UNIFIED PARKINSON DISEASE RATING SCALE; AGED; BRAIN; BRAIN CORTEX; COGNITIVE DYSFUNCTION; COMPLICATION; METABOLISM; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PROCEDURES;

AGED; BRAIN; CEREBRAL CORTEX; COGNITIVE DYSFUNCTION; DEMENTIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY;

EID: 84963766940     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0152716     Document Type: Article

References (40)

1. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23(6):837-44. doi:10.1002/mds. 21956 PMID: 18307261
2. Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007;22(9):1272-7. PMID: 17415797
3. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010;9(12):1200-13. doi:10.1016/S1474-4422 (10) 70212-X PMID: 20880750
4. Vander BT, Minoshima S, Giordani B, Foster NL, Frey KA, Berent S, et al. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. J Nucl Med 1997;38(5):797-802. PMID: 9170449
5. Peppard RF, Martin WR, Carr GD, Grochowski E, Schulzer M, Guttman M, et al. Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch Neurol 1992;49(12):1262-8. PMID: 1449406
6. Hosokai Y, Nishio Y, Hirayama K, Takeda A, Ishioka T, Sawada Y, et al. Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment. Movement Disorders 2009;24(6):854-862. doi:10.1002/mds.22444 PMID: 19199357
7. Bohnen NI, Koeppe RA, Minoshima S, Giordani B, Albin RL, Frey KA, et al. Cerebral Glucose Metabolic Features of Parkinson Disease and Incident Dementia: Longitudinal Study. Journal of Nuclear Medicine 2011;52(6):848-855. doi:10.2967/jnumed.111.089946 PMID: 21571793
8. Tard C, Demailly F, Delval A, Semah F, Defebvre L, Dujardin K, et al. Hypometabolism in Posterior and Temporal Areas of the Brain is Associated with Cognitive Decline in Parkinson's Disease. J Parkinsons Dis 2015;5(3):569-74. doi:10.3233/JPD-150583 PMID: 26406137
9. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55(3):181-4. PMID: 1564476
10. Katzman R, Zhang MY, Ouang-Ya-Qu, Wang ZY, Liu WT, Yu E, et al. A Chinese version of the Mini-Mental State Examination; impact of illiteracy in a Shanghai dementia survey. J Clin Epidemiol 1988;41(10):971-8. PMID: 3193141
11. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982;17(1):37-49. PMID: 7183759
12. Sheridan LK, Fitzgerald HE, Adams KM, Nigg JT, Martel MM, Puttler LI, et al. Normative Symbol Digit Modalities Test performance in a community-based sample. Arch Clin Neuropsychol 2006;21(1):23-8. PMID: 16139470
13. Zhao Q, Guo Q, Li F, Zhou Y, Wang B, Hong Z. The Shape Trail Test: application of a new variant of the Trail making test. PLoS One 2013;8(2):e57333. doi:10.1371/journal.pone.0057333 PMID: 23437370
14. Steinberg BA, Bieliauskas LA, Smith GE, Ivnik RJ. Mayo's Older Americans Normative Studies: Ageand IQ-Adjusted Norms for the Trail-Making Test, the Stroop Test, and MAE Controlled Oral Word Association Test. Clin Neuropsychol 2005;19(3-4):329-77. PMID: 16120535
15. Lucas JA, Ivnik RJ, Smith GE, Ferman TJ, Willis FB, Petersen RC, et al. Mayo's Older African Americans Normative Studies: norms for Boston Naming Test, Controlled Oral Word Association, Category Fluency, Animal Naming, Token Test, WRAT-3 Reading, Trail Making Test, Stroop Test, and Judgment of Line Orientation. Clin Neuropsychol 2005;19(2):243-69. PMID: 16019707
16. Guo Q, Zhao Q, Chen M, Ding D, Hong Z. A comparison study of mild cognitive impairment with 3 memory tests among Chinese individuals. Alzheimer Dis Assoc Disord 2009;23(3):253-9. doi:10.1097/WAD.0b013e3181999e92 PMID: 19812468
17. Caffarra P, Vezzadini G, Dieci F, Zonato F, Venneri A. Rey-Osterrieth complex figure: normative values in an Italian population sample. Neurol Sci 2002;22(6):443-7. PMID: 11976975
18. Guo Q, Fu JH, Yuan J. A study of validity of a new scoring system of clock drawing test. Chin J Neurol 2008;41(4):234-237.
19. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Movement Disorders 2007;22(12):1689-1707. PMID: 17542011
20. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, et al. Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force. Movement Disorders 2007;22(16):2314-2324. PMID: 18098298
21. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Movement Disorders 2012;27(3):349-356. doi:10.1002/mds.24893 PMID: 22275317
22. Zuo C, Ma Y, Sun B, Peng S, Zhang H, Eidelberg D, et al. Metabolic imaging of bilateral anterior capsulotomy in refractory obsessive compulsive disorder: an FDG PET study. J Cereb Blood Flow Metab 2013;33(6):880-7. doi:10.1038/jcbfm.2013.23 PMID: 23443174
23. Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008;70(16 Pt 2):1470-7. doi:10. 1212/01.wnl.0000304050.05332.9c PMID: 18367705
24. Pappata S, Santangelo G, Aarsland D, Vicidomini C, Longo K, Bronnick K, et al. Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. Neurology 2011;77(14):1357-62. doi:10.1212/WNL.0b013e3182315259 PMID: 21940621
25. Garcia-Garcia D, Clavero P, Gasca Salas C, Lamet I, Arbizu J, Gonzalez-Redondo R, et al. Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging 2012;39(11):1767-1777. doi:10.1007/s00259-012-2198-5 PMID: 22872307
26. Lyoo CH, Jeong Y, Ryu YH, Rinne JO, Lee MS. Cerebral Glucose Metabolism of Parkinson's Disease Patients with Mild Cognitive Impairment. European Neurology 2010;64(2):65-73. doi:10.1159/000315036 PMID: 20606450
27. Nobili F, Abbruzzese G, Morbelli S, Marchese R, Girtler N, Dessi B, et al. Amnestic mild cognitive impairment in Parkinson's disease: A brain perfusion SPECT study. Movement Disorders 2009;24(3):414-421. doi:10.1002/mds.22381 PMID: 19235928
28. Narayanan NS, Rodnitzky RL, Uc EY. Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease. Reviews in the Neurosciences 2013;24(3).
29. Kuhl DE, Metter EJ, Benson DF, Ashford JW, Riege WH, Fujikawa DG, et al. Similarities of Cerebral Glucose-Metabolism in Alzheimers and Parkinsonian Dementia. Journal of Nuclear Medicine 1985;26(5):P69-P69.
30. Perry RH, Tomlinson BE, Candy JM, Blessed G, Foster JF, Bloxham CA, et al. Cortical cholinergic deficit in mentally impaired Parkinsonian patients. Lancet 1983;2(8353):789-90.
31. Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005;65(11):1716-22. PMID: 16344512
32. Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003;60(12):1745-8. PMID: 14676050
33. Shinotoh H, Namba H, Yamaguchi M, Fukushi K, Nagatsuka S, Iyo M, et al. In vivo mapping of brain cholinergic function in Parkinson's disease and progressive supranuclear palsy. Adv Neurol 2001;86:249-55. PMID: 11553984
34. Narayanan NS, Land BB, Solder JE, Deisseroth K, DiLeone RJ. Prefrontal D1 dopamine signaling is required for temporal control. Proceedings of the National Academy of Sciences 2012;109(50):20726-20731.
35. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 1983;275(2):321-8. PMID: 6626985
36. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003;2(4):229-37. PMID: 12849211
37. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009;132(Pt 11):2958-69. doi:10.1093/brain/awp245 PMID: 19812213
38. Gonzalez-Redondo R, Garcia-Garcia D, Clavero P, Gasca-Salas C, Garcia-Eulate R, Zubieta JL, et al. Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process. Brain 2014;137(8):2356-2367.
39. Pedersen KF, Larsen JP, Tysnes OB, Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol 2013;70(5):580-6. doi:10.1001/jamaneurol.2013.2110 PMID: 23529397
40. Broeders M, de Bie RM, Velseboer DC, Speelman JD, Muslimovic D, Schmand B. Evolution of mild cognitive impairment in Parkinson disease. Neurology 2013;81(4):346-52. doi:10.1212/WNL. 0b013e31829c5c86 PMID: 23794682